Bluejay Diagnostics (NASDAQ:BJDX) Rating Increased to Sell at Wall Street Zen

Bluejay Diagnostics (NASDAQ:BJDX) was upgraded by stock analysts at Wall Street Zen to a “sell” rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Bluejay Diagnostics in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Bluejay Diagnostics has a consensus rating of “Sell”.

Bluejay Diagnostics Stock Up 11.5%

BJDX stock opened at $1.45 on Friday. The firm has a 50 day moving average of $2.64 and a two-hundred day moving average of $2.44. Bluejay Diagnostics has a 12 month low of $1.03 and a 12 month high of $16.68. The company has a market capitalization of $1.49 million, a price-to-earnings ratio of -0.12 and a beta of 0.88.

Bluejay Diagnostics (NASDAQ:BJDX) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.95) earnings per share for the quarter.

Insider Activity at Bluejay Diagnostics

In other news, major shareholder Financial Lp Hrt acquired 64,047 shares of Bluejay Diagnostics stock in a transaction dated Thursday, July 9th. The stock was acquired at an average cost of $1.51 per share, for a total transaction of $96,710.97. Following the completion of the purchase, the insider owned 126,993 shares of the company’s stock, valued at $191,759.43. This represents a 101.75% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. 6.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC bought a new position in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned 9.15% of Bluejay Diagnostics at the end of the most recent reporting period. 18.47% of the stock is owned by institutional investors.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.